Application of a combined effect compartment and binding model for gastric acid inhibition of AR-HO47108: A potassium competitive acid blocker, and its active metabolite AR-HO47116 in the dog

European Journal of Pharmaceutical Sciences

Volumn 29, Issue 2, 2006, Pages 91-101

  Äbelö, Angela ^a   Andersson, Magdalena ^a   Holmberg, Ann Aurell ^a   Karlsson, Mats O ^b  

^a ASTRAZENECA R AND D   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Dog; Gastric acid secretion; PK PD modelling; Potassium competitive acid blocker; Reversible inhibition

Indexed keywords

2,3 DIMETHYL 8 (2 ETHYL 6 METHYLBENZYLAMINO)IMIDAZO[1,2 A]PYRIDINE 6 CARBOXAMIDE; 8 (2 ETHYL 6 METHYLBENZYLAMINO) 3 HYDROXYMETHYL 2 METHYLIMIDAZO[1,2 A]PYRIDINE 6 CARBOXAMIDE; AR HO 47108; AR HO 47116; DRUG METABOLITE; HISTAMINE; IMIDAZO[1,2 A]PYRIDINE DERIVATIVE; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING COMPETITION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENCY; DRUG PROTEIN BINDING; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SINGLE DRUG DOSE; STOMACH ACID SECRETION; STOMACH PARIETAL CELL; THEORY;

ANIMALS; DOGS; ENZYME INHIBITORS; GASTRIC ACID; H(+)-K(+)-EXCHANGING ATPASE; IMIDAZOLES; MODELS, BIOLOGICAL; PYRIDINES;

EID: 33748317910     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2006.05.014     Document Type: Article

References (16)

1. Äbelö A., Gabrielsson J., Holstein B., Eriksson U.G., Holmberg J., and Karlsson M.O. Pharmacodynamic modelling of reversible gastric acid pump inhibition in dog and man. Eur. J. Pharm. Sci. 14 (2001) 339-346
2. Beal S.L., and Sheiner L.S. NONMEM User's Guide NONMEM Project Group (1992), University of California at San Francisco, San Francisco
3. Dayneka N.L., Garg V., and Jusko W.J. Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm. 21 (1993) 457-478
4. Friberg L., Brindley C.J., Karlsson M.O., and Devlin A.J. Models of schedule dependent haematological toxicity of 2′-deoxy-2′-methylidenecytidine (DMDC). Eur. J. Clin. Pharmacol. 56 (2000) 567-574
5. Jonsson E.N., and Karlsson M.O. Xpose-an S-Plus-based population pharmacokinetic/pharamacodynamic model building aid for NONMEM. Comput. Method Prog. Biomed. 58 (1999) 51-64
6. Jusko W.J., and Ko H.C. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin. Pharmacol. Ther. 56 (1994) 406-419
7. Jusko W.J., Ko H.C., and Ebling W.F. Convergence of direct and indirect pharmacodynamic response models. J. Pharmacokinet. Biopharm. 23 (1995) 5-8
8. Kerbusch T., Milligan P.A., and Karlsson M.O. Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data. Br. J. Clin. Pharm. 57 (2004) 170-180
9. Moghadamnia A.A., Rostami-Hodjegan A., Abdul-Manap R., Wright C.E., Morice A.H., and Tucker G.T. Physiologically-based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition. Br. J. Clin. Pharmacol. 56 (2003) 57-67
10. +)-transporting ATPase as both potential therapeutic agents and probes of pump function. Biochem. Soc. Trans. 20 (1992) 566-572
11. Rydberg T., Jönsson A., Karlsson M.O., and Melander A. Concentration-effect relationships of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. Br. J. Clin. Pharmacol. 43 (1997) 373-381
12. Sadray S., Jonsson E.N., and Karlsson M.O. Likelihood-based diagnostics for influential individuals in non-linear mixed effects model selection. Pharm. Res. 16 (1999) 1260-1265
13. Sheiner L.B., Stanski D.R., Vozeh S., Miller R.D., and Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin. Pharmacol. Ther. 25 (1979) 358-371
14. Verotta D., and Sheiner L.B. A general model for non-steady state pharmacokinetic/pharmacodynamic data. J. Pharmacokinet. Biopharm. 23 (1995) 1-4
15. +-ATPase and acid secretion by SCH28080, a substituted pyridyl-(1,2a)-imidazole. J. Biol. Chem. 262 (1987) 2077-2084
16. Zuideveld K.P., Rusiς-Pavletiς J., Maas H.J., Peletier L.A., Van der Graaf P.H., and Dahnhof M. Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats. J. Pharmacol. Exp. Ther. 303 (2002) 1130-1137